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We previously documented an important relationship between CBS expression/activity and increased in vitro and in vivo sensitivity to cytosine arabinoside (ara-C), which contributes to the significantly high event-free survival (EFS) rates of DS children with acute myeloid leukemia (AML). 2, 3 In this study, we examined the frequency of the 844ins68 CBS polymorphism and point mutations in CBS exon 8 in myeloblast samples from DS and non-DS children with AML, and in mononuclear cells from healthy, non-leukemic DS children. Myeloblasts from newly diagnosed pediatric AML patients were obtained from the Children's Hospital of Michigan cell bank and from patients treated on the Pediatric Oncology Group (POG) 9421 chemotherapy protocol as previously reported.
2 Genomic DNA samples from healthy, non-leukemic DS children were obtained by venipuncture. Genomic DNAs were extracted from buccal swabs of healthy adult subjects. The research protocol was approved by the Human Investigation Committee of Wayne State University.
CBS exon 8 was amplified in genomic DNAs from myeloblasts of DS and non-DS AML patients, healthy non-leukemic DS individuals and healthy adults using sense (5′-GCATGTCCAGGCGGGGCTTTTG CTG-3′) and antisense (5′-ACTGTGGCCGGGCTCT-GGACTCGAC To obtain adequate amplification of CBS cDNAs containing exon 8, semi-nested PCR reactions were performed using sense (5′-TGCCTCC GAGTCCCCACATCACCA-3′ and 5′-GCACTGGGGGCTGAGATTGT GAGGAC-3′) and antisense (5′-CGCCTCCTCATCGTTGCTCTTGAAC CAC-3′) primers. Final PCR products (447 bp) were isolated with the Concert Rapid Gel Extraction Kit (Life Technologies, Rockville, MD, USA) from a 1.5% agarose gel stained with ethidium bromide and sequenced. The Fisher's exact test was used to compare the frequencies of the CBS 844ins68 polymorphism and wild-type CBS exon 8 sequence between the different patient groups and differences in ara-C IC 50 values were compared between the groups utilizing the Mann-Whitney test.
The 844ins68 polymorphism was detected at a 4.6-fold (P Ͻ 0.001) higher frequency in DS myeloblasts compared to non-DS myeloblasts ( Table 1 ). The gene variant was also detected in genomic DNA samples from healthy control subjects, similar to the non-DS myeloblasts and consistent with the frequencies reported previously in the general population (Table 1) . 1 The polymorphism was detected in an approximately two-fold higher frequency in blood samples from healthy, non-leukemic DS individuals compared to the non-leukemic DS population. The difference between the frequencies of the polymorphism in DS myeloblasts and non-leukemic DS blood samples was also statistically significant (P = 0.04). In all the DS and non-DS cases Leukemia for which the 68-bp insertion was detected, it was present in the heterozygous state. The intensity of the bands indicated that the 844ins68 variant was present in two of the three alleles of several of the analyzed samples from both the DS AML and non-leukemic DS groups ( Figure 1 ).
The amplicons for 16 samples each from the DS AML, non-DS AML, and non-leukemic DS groups were sequenced to determine if the two well characterized point mutations in CBS exon 8, T 833 C and G 919 A were also present. All the sequenced samples from the three groups which contained the 844ins68 gene variant, also contained the T 833 C in the mutated CBS allele, as has been reported. 1 The G 919 A mutation was not detected in any of the 48 samples sequenced nor was the T 833 C mutation detected independent of the 844ins68 polymorphism.
To determine whether DNA samples which contained the 844ins68 polymorphism resulted in the transcription of an altered CBS transcript, a semi-nested RT-PCR reaction was used to amplify CBS exon 8 in cDNA prepared from total RNA from eight DS and eight non-DS leukemia cells. For both wild-type and 844ins68, 447 bp products were detected, suggesting that the 844ins68 gene variant did not result in any alteration of the CBS transcripts. Sequencing of the transcripts confirmed the presence of only wild-type transcripts in both wild-type and 844ins68 samples.
No previous studies reported to date have determined the frequency of the 844ins68 CBS gene variant in a DS population. However, Barbaux et al 4 examined the relationship of this polymorphism in children with a range of IQs and detected a lower frequency among children with higher IQs. The converse observation of a higher frequency of the polymorphism in children with lower IQs (ie DS) would be in keeping with the results of our DS study. In view of the very high frequency of the polymorphism in the DS AML group, it can be speculated that the 844ins68 variant may be linked to the greater incidence of AML (and particularly the megakaryocytic phenotype) in DS children compared to non-DS children. Studying the frequency of the 844ins68 polymorphism in both DS and non-DS ALL patients would better identify any association with the DS leukemia phenotype, in general, or more specifically, DS AML cases.
Does the presence of the 844ins68 polymorphism in CBS exon 8 have any functional significance, particularly in the case of leukemia? DS myeloblasts with the polymorphism (n = 7) were approximately 6.9-fold more sensitive to ara-C compared to the DS AML group with the wild-type CBS allele (n = 7) (median ara-C IC 50 : 33.6 nmol/l vs 230.8 nmol/l, respectively; P Ͻ 0.002). For the non-DS AML group, there was a trend towards myeloblasts containing the 844ins68 gene variant (n = 5) showing increased ara-C sensitivity compared to myeloblasts without the gene variant (n = 39). Excluding one sample with a disproportionate degree of ara-C resistance (IC 50 Ͼ2000 nmol/l), the four non-DS myeloblast samples with the 844ins68 variant were 1.85-
Figure 1
PCR amplification of CBS exon 8 from genomic DNA and identification of the CBS 844ins68 polymorphism. Exon 8 of the cystathionine-␤-synthase gene was amplified by PCR from genomic DNAs extracted from diagnostic myeloblasts (upper and middle panel) and peripheral blood mononuclear cells (lower panel). The 844ins68 CBS gene allele was distinguished from the wild-type CBS allele by fractionation of the PCR products on 2% agarose gels with ethidium bromide staining. The 211 bp fragment represented the wild-type allele and the 279 bp product represented the polymorphic allele.
fold more sensitive to ara-C compared to myeloblasts without the polymorphism (median ara-C IC 50 : 233.2 nmol/l vs 432.3 nmol/l, respectively; P = 0.1); while this difference was not statistically significant, this may possibly be due to the small sample size.
Conflicting studies have been reported regarding the biochemical effects of the 844ins68 polymorphism on homocysteine levels. Tsai et al 5 demonstrated that carriers of the 844ins68 polymorphism had significantly lower total plasma homocysteine levels following methionine loading and concluded that this polymorphism was associated with higher CBS enzyme activities. However, Silaste et al 6 did not observe differences in plasma homocysteine levels between patients with or without the polymorphism. Barbaux et al 4 theorized that the 844ins68 polymorphism may be in linkage disequilibrium with other gene abnormalities. Thus, further studies in cell models and clinical samples are clearly warranted to identify the biological effects of the 844ins68 polymorphism.
The study of CBS gene polymorphisms complements additional studies that have examined the relationships between DS and frequencies of polymorphisms of other genes that encode for enzymes involved in the intracellular reduced folate pathway. Methylene tetrahydrofolate reductase (MTHFR) catalyzes the conversion of 5,10-methylene tetrahydrofolate to 5-methyltetrahydrofolate, which serves as the methyl donor for the remethylation of homocysteine to methionine. The C677T mutation is associated with an alanine to valine substitution, and results in an enzyme with reduced catalytic activity. The heterozygous genotype is present in approximately 30% of the population, while the homozygous variant (T/T) is present in approximately 10% of the population. James et al 7 reported that not only do mothers of DS individuals have altered folate metabolism, but mothers with the C677T allele had a 2.6-fold higher risk of having a DS child. In a larger sample size, the C677T allele was analyzed along with a polymorphism in the methionine synthase reductase (MTRR) gene. The combined presence of both polymorphisms was associated with a four-fold greater risk of having a DS child. Based on these results, the analysis of the frequencies of polymorphic variants of other genes involved in folate metabolism (eg reduced folate carrier, methionine synthase) in DS would appear to be warranted and may provide additional insights into the relationship between the altered folate metabolism in DS individuals and their mothers.
The further study of CBS gene variants and, the 844ins68 polymorphism, in particular, may further identify the relationships between the phenotypic features of DS, including mental retardation, the increased risk of acute leukemia, and the increased chemotherapy sensitivity of DS AML patients. 1 1 
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TO THE EDITOR
Chronic myelogenous leukemia is characterized by a reciprocal translocation, t(9;22)(q34;q11), between the long arms of chromosomes 9 and 22, leading to the Philadelphia chromosome. Two fusion genes are created by this translocation: bcr/abl and abl/bcr. The fusion regions of both translocation products are unique and strictly limited to leukemia cells, giving rise to potential tumor-specific antigens.
Current treatment options for CML include stem cell transplantation, and hydroxyurea-based or interferon-␣-based regimens. 1 Much attention has been focused recently on the newly introduced tyrosine kinase inhibitor STI571 with its striking effect in almost all patients. However, resistance to STI571 as a single agent occurs frequently and rapidly, and allogeneic stem cell transplantation is still regarded as the only curative treatment for CML. The latter is thought to depend on a T cell-mediated graft-versus-leukemia effect (GVL) distinct from the graft-versus-host effect, suggesting specific recognition of tumor cells by the immune system. This effect may also be achieved by administration of donor leukocyte infusions after relapse in transplant recipients. Although GVL is largely caused by differences in major and minor histocompatibility antigens between donor and recipient, there is also evidence for leukemia-specific recognition. Vaccination with tumor-specific antigens could enhance or initiate antileukemic effects. 2 However, little is known about the nature of such potential CMLspecific tumor antigens. Research has focused on the Bcr/Abl proteins, known to cause the disease. Whereas several studies on the immunogenicity of peptides spanning the fusion region of bcr/abl have appeared, nothing is known about the corresponding reciprocal translocation product abl/bcr, the expression of which can be detected at the mRNA level in the majority of CML patients. Depending on the location of the breakpoint, different isoforms are present: a1b-b3 or a1a-b3 corresponding to the b2a2 fusion and a1b-b4 or a1a-b4 corresponding to the b3a2 fusion. Previous studies have shown that the a1bb3 and a1bb4 transcripts predominate, and that a1ab3 and a1ab4 are expressed only rarely and then always together with the a1b forms. 3 Several peptides derived from the fusion region of the abl/bcr product have been shown to bind to HLA class I molecules in vitro. 4 To investigate the potential immunogenicity of the abl/bcr fusion region, we selected two strongly HLA-A2 binding peptide sequences, comprising the a1bb3 (FVEHDDESPGL) and a1bb4 (FVEHDLYCTL) fusion region respectively, and attempted to sensitize T cells of healthy HLA-A2-positive donors in vitro against them. Autologous dendritic cells were generated from peripheral blood monocytes by in vitro culture with GM-CSF and IL-4. After TNF␣-induced maturation, DC were pulsed with the respective peptide and used as APC in the priming. T cell cultures were restimulated weekly with irradiated peptidepulsed T2 cells. After two rounds of restimulation, IL-2 was added 1 day after the restimulation. After six to eight restimulations, T cell cultures were tested for peptide-specific cytotoxicity. At that time T cell cultures were Ͼ95% CD3-positive, Ͼ80% CD8-positive, Ͻ20% CD4-positive and Ͻ1% CD56-positive as detected by flow cytometry prior to specificity testing. From two of the four donors tested, we obtained T cell lines recognizing the sensitizing peptides. T cell lines B360 and B363, derived from two different donors sensitized against the a1bb3 peptide, lysed T2 cells pulsed with the a1bb3 peptide but not T2 cells pulsed with an HLA-A2-binding control peptide (Figure 1a) . This showed that these T cell lines specifically recognize the a1bb3 peptide presented by HLA-A2 molecules on T2 cells. For the a1bb4 peptide, we also obtained two T cell lines from different donors, designated B460 and B463, specifically recognizing a1bb4 (Figure 1b) . NK cell activity was excluded in all cases as none of these T cell lines lysed the NK cell target K562 in concurrent experiments. The experiments were repeated with the same cells on different occasions with similar results. Thus, synthetic peptides derived from the fusion region of a1bb3 as well as a1bb4 not only bind to HLA-A2 molecules, but these peptide-MHC complexes can be recognized specifically by peripheral CD8 + T cells from healthy donors. Having demonstrated the immunogenicity of these synthetic abl/bcr peptides, it was important to establish whether the peptide-reactive cell lines would also be able to recognize native CML cells. Abl/bcr + cells from two chronic-phase HLA-A*0201 + CML patients were chosen as target cells. CML8 showed a1bb4 expression whereas CML9 expressed a1bb3. Instead of the weekly restimulation with T2 cells, 1 × 10 6 T cells of each peptide-specific line were incubated with 1 × 10 6 CML cells. After 24 h supernatants were harvested, and tested for TNF␣ content by a standard ELISA. The T cell lines B360 and B363, specific for the a1bb3 fusion peptide, reacted with strong TNF␣ secretion to the a1bb3 These data demonstrate the immunogenicity of peptides derived from the fusion region of abl/bcr fusion gene products in vitro, and moreover, that CML cells can be recognized by peptide-sensitized T
